• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Call Text Chat Email Refer a Patient Join a Study

Search

Hide Search
MotherToBaby

MotherToBaby

Medications and More during pregnancy and breastfeeding

Shopping Cart
Show SearchSearch
Show SearchSearch
  • About
    • Our Work
    • Our Team
    • About OTIS
    • OTIS Membership
    • In Your Area
    • Our Partners
    • Our Impact
    • Member Recognition
  • Exposures
    • Pregnancy and Breastfeeding Exposures
    • Fact Sheets
    • Baby Blogs
    • Podcasts
    • Webinars
    • Interactive Tool
    • Infographics
    • LactRx App
  • Studies
    • Ongoing Studies
    • What’s Involved?
    • Join Now
    • Refer a Patient
    • Health Providers
    • Pharma Industry
    • Publications
  • Health Professionals
    • Patient Education and Provider Resources
    • Refer a Patient
    • Request Materials
    • Annual Meeting
    • Exhibiting Schedule
    • FAQs
    • OTIS Membership
  • Media
    • Media Requests
    • Press Releases
    • eNews Sign Up
  • Donate
  • Contact
  • Show SearchSearch

Molnupiravir

March 1, 2026

Selected References:

  • DeSisto CL, et al. 2021. Risk of stillbirth among women with and without COVID-19 at delivery hospitalization – United States, March 2020 – September 2021. MMWR Morb Mortal Wkly Rep. 70(47):1640-1645.  
  • Hashemian SMR, et al. 2022. RdRp inhibitors and COVID-19: Is molnupiravir a good option? Biomed Pharmacother. 146:112517. 
  • Li G. et al. 2023. Therapeutic strategies for COVID-19: progress and lessons learned. Nat Rev Drug Discov. 22(6):449-475.  
  • Kasehagen L, et al. 2021. COVID-19 – associated deaths after SARS-CoV-2 infection during pregnancy – Mississippi, March 1, 2020 – October 6, 2021. MMWR Morb Mortal Wkly Rep. 70(47):1646-1648. 
  • Merck Sharp & Dohme LLC. 2024. Lagevrio product labeling. Available at: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=1b0da643-ab23-4a0b-a9ec-a434522446d0&type=display. Accessed 10 August 2026.  
  • Pagliano P et al. 2022. The preclinical discovery and development of molnupiravir for the treatment of SARS-CoV-2 (COVID-19). Expert Opin Drug Discov. 17(12):1299-1311.  
  • Regan AK, et al. 2022. SARS-CoV-2 infection during pregnancy and associated perinatal health outcomes: a national US cohort study. J Infect Dis. 225(5):759-767.  
  • U.S. Food & Drug Administration, Antimicrobial Drugs Advisory Committee. November 30, 2021. Molnupiravir. Available at: https://www.fda.gov/media/165856/download. Accessed 10 August 2026. 
  • U.S. Food & Drug Administration. 2021 (Revised October 2023). Fact Sheet for Healthcare Providers: Emergency Use Authorization for Molnupiravir. Available at https://www.fda.gov/media/155054/download. Accessed 10 August 2026. 
  • Wan EYF, et al. 2025. Comparative effectiveness of combination therapy with nirmatrelvir-ritonavir and molnupiravir versus monotherapy with molnupiravir or nirmatrelvir-ritonavir in hospitalized COVID-19 patients: A target trial emulation study. Int J Infect Dis161:108097. 

Footer

               

Hot Links

  • Home
  • Exposures
  • Fact Sheets
  • Baby Blogs
  • Podcasts
  • Pregnancy Studies
  • Join a Study Now
  • Healthcare Professionals
  • Refer a Patient
  • Request Materials
  • News
  • Donate
  • Ask An Expert

Current Studies

  • Ankylosing Spondylitis
  • Eczema (Moderate-to-Severe)/Atopic Dermatitis
  • Hidradenitis Suppurativa
  • Lupus
  • Multiple Sclerosis
  • Non-Radiographic Axial Spondyloarthritis
  • Psoriasis
  • Psoriatic Arthritis

Contact

Exposure Information Service
866.626.6847

Pregnancy Studies
877.311.8972

Media Inquiries
619.368.3259
nchavez@mothertobaby.org

MotherToBaby, a service of the Organization of Teratology Information Specialists

Copyright © 2026 The Organization of Teratology Information Specialists

  • Accessibility
  • Privacy
  • Terms
  • Site Map
^

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $1,200,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.